At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,811 enrolled
Drug / intervention
Rimegepant +1 moredrug
Likely dose
Rimegepant 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Rimegepant and Placebo for Migraine, With or Without Aura. Completed, enrolled 1,811 participants across 69 sites.
Detailed Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedMar 2018
Primary CompletionOct 2018
Study CompletionOct 2018
TodayJul 2026
First PostedMar 12, 2018
Enrollment StartFeb 27, 2018
Primary CompletionOct 8, 2018
Study CompletionOct 15, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.3 years ago
Interventions
Rimegepantdrug
75 mg ODT QD
Placebodrug
Placebo ODT to match rimegepant dose QD